Healthcare -
Biotechnology - NASDAQ - US
$ 1.2
-7.69 %
$ 899 K
Market Cap
None
P/E
1. INTRINSIC VALUE
2. FUNDAMENTAL
ANALYSIS
Price Chart WINT
FINANCIALS
Balance Sheet
Windtree Therapeutics, Inc.
| Current Assets | 5.38 M |
| Cash & Short-Term Investments | 4.32 M |
| Receivables | 0 |
| Other Current Assets | 1.06 M |
| Non-Current Assets | 27 M |
| Long-Term Investments | 0 |
| PP&E | 1.63 M |
| Other Non-Current Assets | 25.4 M |
| Current Liabilities | 4 M |
| Accounts Payable | 809 K |
| Short-Term Debt | 669 K |
| Other Current Liabilities | 2.52 M |
| Non-Current Liabilities | 25 M |
| Long-Term Debt | 16.2 M |
| Other Non-Current Liabilities | 8.86 M |
EFFICIENCY
Earnings Waterfall
Windtree Therapeutics, Inc.
| Revenue | 0 |
| Cost Of Revenue | 82 K |
| Gross Profit | -82 K |
| Operating Expenses | 17.5 M |
| Operating Income | -17.5 M |
| Other Expenses | 2.75 M |
| Net Income | -20.3 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Windtree Therapeutics, Inc.
| Net Income | -20.3 M |
| Depreciation & Amortization | 82 K |
| Capital Expenditures | -15 K |
| Stock-Based Compensation | 1.28 M |
| Change in Working Capital | 2.02 M |
| Others | 4.93 M |
| Free Cash Flow | -13.5 M |
Wall Street Analysts Price Targets
Windtree Therapeutics, Inc.
WINT has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
WINT does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Windtree Therapeutics, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
4.94 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics
-- Evofem's Cost to Manufacture PHEXXI will Decrease by 55% - 60% -- SAN DIEGO , March 26, 2025 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) (Evofem or the Company) today announced that it has entered into a License and Supply Agreement (L&S Agreement) with Windtree Therapeutics, Inc. (NasdaqCM: WINT), under which Windtree will be Evofem's sourcing partner for PHEXXI® (lactic acid, citric acid and potassium bitartrate). This FDA-approved hormone-free contraceptive vaginal gel is applied 0 to 60 minutes before each act of intercourse.
prnewswire.com
- 3 weeks ago
Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules
WARRINGTON, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating biotech and advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that the Company received notice from The Nasdaq Stock Market LLC ("Nasdaq") that Windtree has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq. The Company will be subject to a mandatory panel monitor until March 20, 2026.
globenewswire.com
- 4 weeks ago
Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved Product
WARRINGTON, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating biotech and advancing early and late-stage innovative therapies for critical conditions and diseases, is pleased to announce that it has entered into a License and Supply Agreement to become the sourcing partner for Evofem Biosciences, Inc. (OTCQB: EVFM) for one of Evofem's FDA-approved products -- PHEXXI® (lactic acid, citric acid and potassium bitartrate).
globenewswire.com
- 1 month ago
Windtree Strengthens Global Intellectual Property Portfolio with New Japanese Patent For the Company's Oncology Pipeline
The Company's oncology aPKCi inhibitor is a novel, first in class drug candidate The Company's oncology aPKCi inhibitor is a novel, first in class drug candidate
globenewswire.com
- 3 months ago
WINT and Ferguson announce strategic collaboration to elevate water management and leak mitigation for real estate and construction
Industry leaders deliver comprehensive distribution of AI-based water management, protection and risk mitigation solutions throughout the U.S. NEW YORK, Jan. 14, 2025 /PRNewswire/ -- WINT Water Intelligence, a global leader in cutting-edge water management and leak-prevention solutions, announces a strategic collaboration with Ferguson, the largest value-added distributor of plumbing supplies, PVF, waterworks, and fire and fabrication products in the United States. WINT's solutions are now available to Ferguson's extensive distribution network, offering a broader selection of advanced technologies that complement Ferguson's existing commercial building solutions.
prnewswire.com
- 3 months ago
Windtree Announces the Addition of Leanne Kelly to Its Board of Directors
WARRINGTON, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced the appointment of Leanne Kelly to its board of directors (“Board”). Ms. Kelly has significant public company executive experience and joins the Board as an independent director and chair of the audit committee.
globenewswire.com
- 3 months ago
Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia
WARRINGTON, Pa., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that it has filed a new istaroxime PCT patent application entitled, “ISTAROXIME DERIVATIVES THEREOF FOR PREVENTING OR REDUCING THE RISK OF ACUTE MYOCARDIAL ARRHYTHMIA.”
globenewswire.com
- 4 months ago
Windtree Announces Partnership with New Growth Advisors to Leverage Positive Phase 2 Istaroxime Study in Cardiogenic Shock for a Potential Strategic Transaction
WARRINGTON, Pa., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that it has engaged New Growth Advisors (“NGA”), a leading life sciences consulting firm chosen by companies seeking discreet, conflict-free, and knowledgeable advice on complex M&A, asset sale, research, capital markets, and licensing transactions, as its strategic advisor to lead a process in respect of Windtree's cardiovascular portfolio, including a potential out-licensing transaction or asset sale. NGA has advised on transactions with an aggregate value approaching $400 million from 2023 through 2024.
globenewswire.com
- 4 months ago
Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business Updates
WARRINGTON, Pa., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the third quarter ended September 30, 2024 and provided key business updates.
globenewswire.com
- 4 months ago
Windtree Announces Istaroxime Cardiogenic Shock Patent Filings In Countries Around the World
WARRINGTON, Pa., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that the Company has completed national phase filings of patent applications around the world, including in the United States, Germany, France, Italy, Japan and China.
globenewswire.com
- 5 months ago
Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Japan
WARRINGTON, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced the issuance of an istaroxime patent for Japan. The patent is entitled, “Istaroxime-containing intravenous formulation for the treatment of heart failure (AHF).” The claims are directed to intravenous administration of istaroxime using increased infusion times alone or in combination with other agents useful to treat AHF, thereby improving treatment of heart failure and diastolic relaxation when compared to conventional protocols. The application has been accorded Patent No. 7560134 with a registration date of September 24, 2024 and will expire in 2039.
globenewswire.com
- 6 months ago
Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock
Istaroxime treatment significantly improved systolic blood pressure as well as cardiac output and renal function without increasing heart rate or clinically significant arrythmias
globenewswire.com
- 6 months ago
8. Profile
Summary
Windtree Therapeutics, Inc. WINT
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 899 K
Dividend Yield
0.33%
Description
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee's Pharmaceutical Holdings Limited.
Contact
2600 Kelly Road, Warrington, PA, 18976-3622
https://windtreetx.com
IPO
Date
Aug. 7, 1995
Employees
20
Officers
Mr. Jed A. Latkin
Chief Executive Officer & Director
Ms. Tracy Rarick
Head of Operations & Program Management
Mr. Eric L. Curtis M.B.A.
President & Chief Operating Officer
Dr. Steven G. Simonson M.D., M.H.S
Senior Vice President & Chief Medical Officer
Dr. Pratap Paruchuru
Executive Director of Clinical Development
Mr. George Cox
Vice President of Technical Operations
Ms. Jamie McAndrew
Senior Vice President, Chief Financial Officer, Chief Accounting Officer, Controller & Corporate Secretary